Immunotherapy has helped improve the prognosis of metastatic lung cancer. However, only about 40% of patients respond to conventional immunotherapy with anti-PD(L)-1 agents. This research aims to identify biomarkers of response to immunotherapy at the tumor level and to characterize new therapeutic targets
Patients aged 18 years or older, male or female.
Willing to participate in the study and having signed a written informed consent form.
Presenting a strong suspicion of localized resectable or advanced unresectable non-small cell lung cancer, or having a histologically confirmed non-small cell lung cancer.
Affiliated with a social security system or benefiting from such a system.
Individuals in an emergency situation, adults under legal protection (guardianship, curatorship, or judicial protection), or individuals unable to provide informed consent.
Inability to comply with the medical follow-up required by the study for geographical, social, or psychological reasons.
History of solid organ transplantation or hematopoietic stem cell transplantation.
Pregnant or breastfeeding women.